

MEDICAL ONCOLOGY

Maintenance of Certification Examination (MOC) / General LKA



Effective beginning with the Fall 2026 traditional, 10-year MOC exam and the 2026 Quarter 3 Longitudinal Knowledge Assessment.

High Relevance: Topics are very likely to appear on the assessment.

Medium Relevance: Topics are moderately likely to appear on the assessment.

Low Relevance: Topics will not appear on the assessment.

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|---|-----------------------|------------------------------|-------------------------------------|--|---|
| 1 Clinical Research Methodology and Ethics | 6.5% | | | | |
| 1.1 Clinical research methodology | 4.5% | HIGH | HIGH | HIGH | HIGH |
| 1.1.1 Design and interpretation of clinical trials | | | | | |
| 1.1.1.1 Clinical trial design | | | | | |
| 1.1.1.2 Clinical trial interpretation | | | | | |
| 1.1.2 Tumor assessment, imaging, and end points | | | | | |
| 1.2 Ethics | 2% | HIGH | HIGH | HIGH | LOW |
| 1.2.1 Human subjects and regulatory and legal issues | | | | | |
| 1.2.2 Conflict of interest | | | | | |
| 2 Palliative Care, Survivorship, and Oncologic Complications | 11% | | | | |
| 2.1 Clinical manifestations of advanced cancer and its treatment | 2.5% | HIGH | HIGH | HIGH | HIGH |
| 2.1.1 Cutaneous and mucosal manifestations | | | | | |
| 2.1.2 Endocrine manifestations | | | | | |
| 2.1.3 Gastrointestinal manifestations | | | | | |
| 2.1.4 Hematologic manifestations | | | | | |
| 2.1.5 Musculoskeletal manifestations | | | | | |
| 2.1.6 Neurologic manifestations | | | | | |
| 2.1.7 Renal, metabolic, and nutritional manifestations | | | | | |
| 2.1.8 Paraneoplastic syndromes | | | | | |
| 2.1.9 Cardiothoracic manifestations | | | | | |
| 2.1.10 Fatigue | | | | | |
| 2.1.11 Psychiatric manifestations | | | | | |
| 2.1.12 Infectious risks and complications | | | | | |
| 2.1.13 Lymphedema | | | | | |
| 2.2 Cancer pain | 3.5% | LOW | HIGH | HIGH | HIGH |
| 2.2.1 Use of opioids | | | | | |
| 2.2.2 Use of nonopioids | | | | | |
| 2.3 Survivorship issues | 1% | HIGH | HIGH | HIGH | HIGH |
| 2.3.1 Fertility and sexual health | | | | | |
| 2.3.2 Second primary cancers | | | | | |
| 2.3.3 Secondary cancer prevention | | | | | |

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|--|-----------------------|------------------------------|-------------------------------------|--|---|
| 2.3.4 Nonmalignant sequelae | | | | | |
| 2.3.5 Surveillance | | | | | |
| 2.4 End-of-life issues | 2% | HIGH | HIGH | HIGH | HIGH |
| 2.4.1 Hospice | | | | | |
| 2.4.2 Feeding and nutrition | | | | | |
| 2.4.3 Decision making/communication | | | | | |
| 2.5 Communication, including prognosis, goals of care, and survivorship | 2% | LOW | HIGH | HIGH | LOW |
| 2.5.1 Communicating prognosis and other clinical information | | | | | |
| 2.5.2 Discussing goals of care | | | | | |
| 2.5.3 Discussing survivorship issues | | | | | |
| 3 Hematologic Neoplasms | 13% | | | | |
| 3.1 Acute leukemia and myelodysplasia | 2% | HIGH | HIGH | HIGH | MEDIUM |
| 3.1.1 Acute myeloid leukemia (AML) | | | | | |
| 3.1.1.1 Acute promyelocytic leukemia (APL) | | | | | |
| 3.1.1.2 AML with recurrent genetic abnormalities | | | | | |
| 3.1.1.3 AML with myelodysplasia-related changes | | | | | |
| 3.1.1.4 AML not otherwise specified | | | | | |
| 3.1.1.5 Myeloid sarcoma | | | | | |
| 3.1.2 Acute lymphoblastic leukemia/lymphoma | | | | | |
| 3.1.3 Myelodysplastic syndromes | | | | | |
| 3.1.4 Chronic myelomonocytic leukemia | | | | | |
| 3.2 Chronic myeloid leukemia and myeloproliferative neoplasms | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 3.2.1 Chronic myeloid leukemia | | | | | |
| 3.2.2 Myeloproliferative neoplasms | | | | | |
| 3.3 Chronic lymphoproliferative leukemias | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 3.3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma | | | | | |
| 3.3.2 Hairy cell leukemia | | | | | |
| 3.3.3 T-cell prolymphocytic leukemia | | | | | |
| 3.3.4 T-cell large granular lymphocytic leukemia | | | | | |
| 3.3.5 Monoclonal B-cell lymphocytosis | | | | | |
| 3.4 Hodgkin lymphoma | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 3.4.1 Early-stage disease | | | | | |
| 3.4.2 Advanced disease | | | | | |
| 3.5 Multiple myeloma and plasma cell dyscrasias | 3% | HIGH | HIGH | MEDIUM | MEDIUM |
| 3.5.1 Multiple myeloma/plasma cell leukemia | | | | | |
| 3.5.2 Solitary plasmacytoma | | | | | |
| 3.5.3 Primary amyloidosis | | | | | |

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|--|-----------------------|------------------------|-------------------------------|---|-----------------------------------|
| 3.5.4 Monoclonal gammopathy of undetermined significance (MGUS) | | | | | |
| 3.5.5 Lymphoplasmacytic lymphoma (including Waldenstrom macroglobulinemia) | | | | | |
| 3.6 Non-Hodgkin lymphoma | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 3.6.1 Diffuse large B-cell lymphoma | | | | | |
| 3.6.2 Follicular lymphoma | | | | | |
| 3.6.3 Burkitt lymphoma | | | | | |
| 3.6.4 Mantle cell lymphoma | | | | | |
| 3.6.5 NK-T cell lymphoma | | | | | |
| 3.6.6 Anaplastic large cell lymphoma | | | | | |
| 3.6.7 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | | | | | |
| 3.6.8 Nodal marginal zone lymphoma | | | | | |
| 3.6.9 Human immunodeficiency virus (HIV)-associated lymphoma | | | | | |
| 3.6.10 Cutaneous T-cell lymphoma | | | | | |
| 3.6.11 Primary central nervous system lymphoma | | | | | |
| 3.6.12 Post-transplantation lymphoproliferative syndromes | | | | | |
| 3.6.13 Peripheral T-cell lymphoma | | | | | |
| 3.7 Genetics and genomics of hematologic neoplasms | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 3.8 Complications of hematologic neoplasm treatment | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 4 Thoracic Cancer | 11.5% | | | | |
| 4.1 Non-small cell lung cancer | 4% | HIGH | HIGH | HIGH | MEDIUM |
| 4.1.1 Early-stage disease | | | | | |
| 4.1.1.1 Resectable disease | | | | | |
| 4.1.1.2 Unresectable disease | | | | | |
| 4.1.2 Locally advanced disease | | | | | |
| 4.1.2.1 Stage IIIA disease | | | | | |
| 4.1.2.2 Stage IIIB disease | | | | | |
| 4.1.2.3 Stage IIIC disease | | | | | |
| 4.1.3 Metastatic disease | | | | | |
| 4.1.3.1 Adenocarcinoma | | | | | |
| 4.1.3.2 Squamous cell carcinoma | | | | | |
| 4.2 Small cell lung cancer | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 4.2.1 Limited disease | | | | | |
| 4.2.2 Extensive disease | | | | | |
| 4.3 Mesothelioma and thymus cancer | 1% | MEDIUM | HIGH | MEDIUM | MEDIUM |
| 4.3.1 Mesothelioma | | | | | |
| 4.3.2 Thymus cancer | | | | | |
| 4.4 Genetics and genomics of thoracic cancer | 2% | HIGH | HIGH | MEDIUM | MEDIUM |

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|--|-----------------------|------------------------|-------------------------------|---|-----------------------------------|
| 4.5 Complications of thoracic cancer treatment | 2.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 5 Breast Cancer | 13.5% | | | | |
| 5.1 Premalignant conditions and high-risk factors | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 5.1.1 High-risk histologies (including atypical ductal hyperplasia and atypical lobular hyperplasia) | | | | | |
| 5.1.2 Genetic predispositions | | | | | |
| 5.2 Carcinoma in situ | 1.5% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 5.3 Early stage and locally advanced invasive carcinoma | 3% | HIGH | HIGH | HIGH | MEDIUM |
| 5.3.1 HER2-positive disease | | | | | |
| 5.3.2 HER2-negative, hormone receptor-positive disease | | | | | |
| 5.3.3 HER2-negative, hormone receptor-negative (triple-negative) disease | | | | | |
| 5.4 Inflammatory disease | 0.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 5.5 Locally recurrent disease | 0.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 5.5.1 In-breast recurrence | | | | | |
| 5.5.2 Chest wall recurrence | | | | | |
| 5.6 Metastatic disease | 3% | HIGH | HIGH | MEDIUM | MEDIUM |
| 5.6.1 HER2-positive metastatic disease | | | | | |
| 5.6.2 HER2-negative, hormone receptor-positive metastatic disease | | | | | |
| 5.6.3 HER2-negative, hormone receptor-negative (triple-negative) metastatic disease | | | | | |
| 5.7 Less common clinical scenarios, including tubular carcinoma, male breast cancer, and pregnancy-associated breast cancer | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 5.7.1 Tubular carcinoma | | | | | |
| 5.7.2 Male breast cancer | | | | | |
| 5.7.3 Pregnancy-associated breast cancer | | | | | |
| 5.8 Genetics and genomics of breast cancer | 1.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 5.9 Complications of breast cancer treatment | 1.5% | HIGH | HIGH | HIGH | MEDIUM |
| 6 Genitourinary Cancer | 12% | | | | |
| 6.1 Germ cell tumors | 1.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 6.1.1 Seminoma | | | | | |
| 6.1.2 Nonseminoma | | | | | |
| 6.1.3 Germ cell tumor type not specified | | | | | |
| 6.2 Prostate cancer | 3% | HIGH | HIGH | MEDIUM | MEDIUM |
| 6.2.1 Localized disease | | | | | |
| 6.2.2 Locally advanced disease | | | | | |
| 6.2.3 Prostate-specific antigen-only nonmetastatic disease | | | | | |
| 6.2.3.1 Castration-sensitive disease | | | | | |
| 6.2.3.2 Castration-resistant disease | | | | | |
| 6.2.4 Metastatic disease | | | | | |
| 6.2.4.1 Metastatic castration-sensitive disease | | | | | |

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|--|-----------------------|------------------------|-------------------------------|---|-----------------------------------|
| 6.2.4.2 Metastatic castration-resistant disease | | | | | |
| 6.2.5 Special issues in prostate cancer | | | | | |
| 6.2.5.1 Small cell carcinoma | | | | | |
| 6.3 Renal cell cancer | 2.5% | MEDIUM | HIGH | MEDIUM | MEDIUM |
| 6.3.1 Localized disease | | | | | |
| 6.3.2 Metastatic disease | | | | | |
| 6.3.3 Non-clear cell histologies | | | | | |
| 6.4 Urothelial and other genitourinary cancers | 2% | MEDIUM | HIGH | MEDIUM | MEDIUM |
| 6.4.1 Bladder cancer | | | | | |
| 6.4.1.1 Non-muscle invasive disease | | | | | |
| 6.4.1.2 Muscle-invasive disease | | | | | |
| 6.4.1.3 Metastatic disease | | | | | |
| 6.4.2 Upper tract urothelial cancer and urethral cancer | | | | | |
| 6.4.3 Rare histologies | | | | | |
| 6.5 Adrenal tumors | 0% | LOW | LOW | LOW | LOW |
| 6.5.1 Adrenocortical carcinoma | | | | | |
| 6.5.2 Pheochromocytoma and paraganglioma | | | | | |
| 6.6 Genetics and genomics of genitourinary cancer | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 6.7 Complications of genitourinary cancer treatment | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 7 Gynecologic Cancer | 5.5% | | | | |
| 7.1 Cervical cancer | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 7.1.1 Local-regional disease (stages II and III) | | | | | |
| 7.1.2 Recurrent and metastatic disease | | | | | |
| 7.2 Ovarian, fallopian tube, and primary peritoneal cancers | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 7.2.1 Epithelial ovarian, fallopian tube, and primary peritoneal cancers | | | | | |
| 7.2.1.1 Stage I | | | | | |
| 7.2.1.2 Stages II-IV | | | | | |
| 7.2.2 Nonepithelial ovarian cancers | | | | | |
| 7.2.3 Low malignant potential (borderline) cancers | | | | | |
| 7.3 Uterine sarcoma | 0.5% | LOW | MEDIUM | LOW | LOW |
| 7.4 Endometrial cancer | 0.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 7.5 Genetics and genomics of gynecologic cancer | 0.5% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 7.6 Complications of gynecologic cancer treatment | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 8 Gastrointestinal Cancer | 13.5% | | | | |
| 8.1 Anal cancer | 1% | MEDIUM | HIGH | MEDIUM | MEDIUM |
| 8.1.1 Local-regional disease | | | | | |
| 8.1.2 Recurrent and metastatic disease | | | | | |

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|--|-----------------------|------------------------|-------------------------------|---|-----------------------------------|
| 8.2 Biliary tree and gallbladder cancer | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 8.2.1 Local-regional disease | | | | | |
| 8.2.2 Recurrent and metastatic disease | | | | | |
| 8.3 Colorectal cancer | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 8.3.1 Colon cancer | | | | | |
| 8.3.1.1 Local-regional disease | | | | | |
| 8.3.1.2 Recurrent and metastatic disease | | | | | |
| 8.3.2 Rectal cancer | | | | | |
| 8.3.2.1 Local-regional disease | | | | | |
| 8.3.2.2 Recurrent and metastatic disease | | | | | |
| 8.4 Esophageal cancer | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 8.4.1 Local-regional disease | | | | | |
| 8.4.2 Recurrent and metastatic disease | | | | | |
| 8.5 Gastric cancer | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 8.5.1 Resectable disease | | | | | |
| 8.5.2 Unresectable and metastatic disease | | | | | |
| 8.6 Hepatocellular cancer | 1% | MEDIUM | HIGH | MEDIUM | MEDIUM |
| 8.6.1 Resectable disease | | | | | |
| 8.6.2 Unresectable, liver-only disease | | | | | |
| 8.6.3 Metastatic disease | | | | | |
| 8.7 Gastrointestinal neuroendocrine tumors | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 8.8 Pancreatic cancer | 1.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 8.8.1 Resectable disease | | | | | |
| 8.8.2 Unresectable disease | | | | | |
| 8.8.3 Metastatic and recurrent disease | | | | | |
| 8.9 Small bowel and appendiceal cancer | 0.5% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 8.9.1 Small bowel cancer | | | | | |
| 8.9.2 Appendiceal cancer | | | | | |
| 8.10 Genetics and genomics of gastrointestinal cancer | 2% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 8.11 Complications of gastrointestinal cancer treatment | 1.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 9 Skin Cancer, Sarcomas, and Unknown Primary Site | 7% | | | | |
| 9.1 Melanoma | 2.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 9.1.1 Localized melanoma | | | | | |
| 9.1.2 Regional nodal and in-transit metastasis | | | | | |
| 9.1.3 Metastatic disease | | | | | |
| 9.2 Squamous cell and basal cell cancer of the skin | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 9.2.1 Local-regional disease | | | | | |

| Blueprint Code and Topic | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | RiskAssessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|---|-----------------------|------------------------|-------------------------------|---|-----------------------------------|
| 9.2.2 Recurrent and metastatic disease | | | | | |
| 9.3 Merkel cell carcinoma | 0% | LOW | LOW | LOW | LOW |
| 9.4 Bone and soft-tissue sarcomas | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 9.4.1 Localized primary disease | | | | | |
| 9.4.2 Local disease recurrence | | | | | |
| 9.4.3 Metastatic disease | | | | | |
| 9.4.4 Gastrointestinal stromal tumor (GIST) | | | | | |
| 9.4.4.1 Local-regional disease | | | | | |
| 9.4.4.2 Recurrent and metastatic disease | | | | | |
| 9.5 Unknown primary site | 1% | HIGH | HIGH | MEDIUM | MEDIUM |
| 9.6 Genetics and genomics of skin cancers, sarcomas, and unknown primary site | 0.5% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 9.7 Complications of treatment for skin cancers, sarcomas, and unknown primary site | 1% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 10 Head, Neck, Thyroid, and Central Nervous System Malignancies | 6.5% | | | | |
| 10.1 Squamous cell carcinoma of the head and neck | 2% | HIGH | HIGH | MEDIUM | MEDIUM |
| 10.1.1 Human papillomavirus-positive disease | | | | | |
| 10.1.1.1 Local-regional disease | | | | | |
| 10.1.1.2 Recurrent and metastatic disease | | | | | |
| 10.1.2 Human papillomavirus-negative disease | | | | | |
| 10.1.2.1 Local-regional disease | | | | | |
| 10.1.2.2 Recurrent and metastatic disease | | | | | |
| 10.2 Salivary gland tumors | 0.5% | MEDIUM | MEDIUM | LOW | LOW |
| 10.3 Thyroid cancer | 0.5% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 10.3.1 Papillary | | | | | |
| 10.3.2 Medullary | | | | | |
| 10.3.3 Anaplastic | | | | | |
| 10.4 Nasopharyngeal carcinoma | 0.5% | MEDIUM | MEDIUM | LOW | LOW |
| 10.4.1 Local and regional disease | | | | | |
| 10.4.2 Metastatic disease | | | | | |
| 10.5 Central nervous system malignancies | 1.5% | HIGH | HIGH | MEDIUM | MEDIUM |
| 10.5.1 Primary central nervous system lesions | | | | | |
| 10.5.1.1 High-grade gliomas (astrocytoma and glioblastoma) | | | | | |
| 10.5.1.2 Oligodendroglioma and other central nervous system lesions | | | | | |
| 10.5.2 Metastatic central nervous system lesions | | | | | |
| 10.5.2.1 Parenchymal metastases | | | | | |
| 10.5.2.2 Meningeal metastases | | | | | |
| 10.6 Genetics and genomics of head, neck, thyroid, and central nervous system malignancies | 0.5% | MEDIUM | MEDIUM | MEDIUM | MEDIUM |
| 10.7 Complications of treatment for head, neck, thyroid, and central nervous system malignancies | 1% | HIGH | HIGH | MEDIUM | MEDIUM |